上海三友医疗器械股份有限公司2025年度业绩快报公告

Financial Performance - The company achieved total operating revenue of 542.79 million yuan, representing a year-on-year increase of 19.66% [3] - Research and development expenses amounted to 83.71 million yuan, accounting for 15.42% of total revenue [3] - The net profit attributable to the parent company was 63.29 million yuan, a significant increase of 451.85% year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 49.67 million yuan, marking a turnaround from loss to profit compared to the previous year [3] Business Development - The company leveraged its innovative therapy advantages to develop new products and expand its product line, leading to stable sales growth [4] - The ultrasound knife business experienced rapid growth in both sales and net profit during the reporting period [4] - The international business continued to grow rapidly, with the subsidiary Implanet achieving operating revenue of 12.47 million euros, a year-on-year increase of 32.62%, particularly strong in the U.S. market with a growth of 49.30% [4] Financial Position - As of the end of the reporting period, total assets were 2,376.83 million yuan, an increase of 3.04% from the beginning of the period [3] - The equity attributable to the parent company was 2,104.89 million yuan, reflecting a 10.10% increase from the beginning of the period [3] Shareholder Equity - The company implemented a capital reserve transfer plan, increasing the share capital by 34.22% during the reporting period [7] - The increase in share capital was due to the transfer of 2 shares for every 10 shares held and the completion of the acquisition of remaining minority shares of the subsidiary [7]